BeiGene to Present Clinical Data from Innovative Oncology Po

Plenary presentation of Phase 3 tislelizumab trial in first-line RM-NPC Primary analysis of zanubrutinib Phase 2 ROSEWOOD trial in follicular lymphoma Long-term data from zanubrutinib Phase 3

Related Keywords

Australia , China , Li Zhang , Zhejiang , Japan , United States , Canada , United Kingdom , America , Great Britain , American , Kuaile Zhao , Emmanuel Bachy , Lai Wang , Kyle Blankenship , Kevin Mannix , Jorgej Castillo , Keun Wook Lee , Julien Edeline , Keun Seok Lee , Jian Li , Jia Fan , Constantines Tam , Eric Van Cutsem , Amgen , Drug Administration , Novartis , Exchange Commission , China National Medical Products Administration , European Union , Bristol Myers Squibb , American Society , Cancer Oncology , Global Head , Gene Poster , Oral Presentations , Chronic Lymphocytic Leukemia , Gastrointestinal Cancer Gastroesophageal , Breast Cancer Metastatic , Seok Lee , Wook Lee , Gene Online Only Abstracts , Lii Cheng , Van Cutsem , Mirati Therapeutics , North America , Novartis Oncology , Private Securities Litigation Reform Act , Beigene , Present , Linical , Data , Rom , Nnovative , Ncology , Portfolio , 022 , Disco , Nnual , Meeting ,